Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)

Archives of Dermatological Research

Volumn 304, Issue 4, 2012, Pages 325-331

  Petramala, Luigi ^a   Giustini, Sandra ^a   Zinnamosca, Laura ^a   Marinelli, Cristiano ^a   Colangelo, Luciano ^a   Cilenti, Giuseppina ^a   Formicuccia, Maria Chiara ^a   D'Erasmo, Emilio ^a   Calvieri, Stefano ^a   Letizia, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bone mineral alterations; Neurofibromatosis type 1; Osteoporosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; COLECALCIFEROL; OSTEOCALCIN; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MASS; BONE MINERAL; BONE REMODELING; CONTROLLED STUDY; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; SPINE; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; CALCIUM; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MINERALS; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OSTEOPOROSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84862835451     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-011-1191-3     Document Type: Article

References (47)

1. Abdel-Wanis M, Kawahara N (2002) Hypophosphatemic osteomalacia in neurofibromatosis 1. hypotheses for pathogenesis and higher incidence of spinal deformity. Med Hypotheses 59:183-185
2. Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G, Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260-284
3. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974-1986
4. Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N (1999) The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 112:835-842 (Pubitemid 29277981)
5. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148 (Pubitemid 26051293)
6. Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis RA, Plon SE, Phillips WA, O'Brian Smith E, Ellis KJ, Lee B (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94:105-111
7. Cho TJ, Seo JB, Lee HR, Yoo WJ, Chung CY, Choi IH (2008) Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1. J Bone Joint Surg Am 90:2735-2744
8. Crawford AH Jr, Bagamery N (1986) Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6:72-88 (Pubitemid 16178104)
9. Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1. results from a pediatric cohort. J Pediatr Orthop 27:472-475 (Pubitemid 46868318)
10. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G (2006) ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 4:441-451 (Pubitemid 44817348)
11. Ferner RE (2010) The neurofibromatosis. Pract Neurol 10:82-93
12. Friedman JM (2002) Neurofibromatosis 1. clinical manifestations and diagnostic criteria. J Child Neurol 17:548-554 (Pubitemid 35203613)
13. Gutmann DH, Wood DL, Collins FS (1991) Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 88:9658-9662 (Pubitemid 21915690)
14. Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K, Peltonen J (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47:583-590
15. Hermanns-Sachweh B, Senderek J, Alfer J, Klosterhalfen B, Büttner R, Füzesi L, Weber M (2005) Vascular changes in the periosteum of congenital pseudarthrosis of the tibia. Pathol Res Pract 201(4):305-312 (Pubitemid 40668481)
16. Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111:1355-1381 (Pubitemid 19028458)
17. Illés T, Halmai V, de Jonge T, Dubousset J (2001) Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12:823-827 (Pubitemid 33086269)
18. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368-381
19. Klein BY, Rojansky N, Gal I, Shlomai Z, Liebergall M, Ben- Bassat H (1995) Analysis of cell-mediated mineralization in culture of bone-derived embryonic cells with neurofibromatosis. J Cell Biochem 57:530-542
20. Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nürnberg P (1998) Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet 7:1261-126.
21. Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, Manjubala I, Fratzl P, Spörle R, Herrmann BG, Parada LF, Kornak U, Mundlos S (2007) Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 16:874-886 (Pubitemid 47062733)
22. Korf BR, Henson JW, Stemmer-Rachamimov A (2005) Case records of the Massachusetts General Hospital. Case 13-2005. A 48-year-old man with weakness of the limbs and multiple tumors of spinal nerves. N Engl J Med 352:1800-1808 (Pubitemid 40570929)
23. Kretzschmar M, Doody J, Massagué J (1997) Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389:618-622 (Pubitemid 27446181)
24. Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J (2004) NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res 19:983-989 (Pubitemid 41103455)
25. Kuorilehto T, Pöyhönen M, Bloigu R, Heikkinen J, Väänänen K, Peltonen J (2005) Decreased bone mineral density and content in neurofibromatosis type 1. lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928-936 (Pubitemid 41127102)
26. Lammert M, Kappler M, Mautner VF, Lammert K, Störkel S, Friedman JM, Atkins D (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16:1161-1166 (Pubitemid 41225104)
27. Lee MJ, Stephenson DA (2007) Recent developments in neurofibromatosis type 1. Curr Opin Neurol 20:135-141 (Pubitemid 46411497)
28. McCormick F (1995) Ras signaling and NF1. Curr Opin Genet Dev 5:51-55
29. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S (2000) Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148:333-342 (Pubitemid 30078245)
30. Morrissy RT, Riseborough EJ, Hall JE (1981) Congenital pseudarthrosis of the tibia. J Bone Joint Surg Br 63B:367-375 (Pubitemid 11039514)
31. Nakamura H, Hirata A, Tsuji T, Yamamoto T (2003) Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 18:1198-1205 (Pubitemid 37294912)
32. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5449 (Pubitemid 37476073)
33. Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, Miyazono K, Rodan GA, Takeuchi Y, Fujita T (2003) Receptor tyrosine kinases inhibit bone morphogenetic protein- Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res 18:827-835 (Pubitemid 37294965)
34. The Consensus Development Panel (1994) National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, 11-13 December 1991. Arch Neurol 51:201-20.
35. Reed AA, Joyner CJ, Brownlow HC, Simpson AH (2002) Human atrophic fracture non-unions are not avascular. J Orthop Res 20:593-599 (Pubitemid 34461020)
36. Riccardi VM (1981) Von Recklinghausen neurofibromatosis. N Engl J Med 305:1617-1627
37. Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42:616-622
38. Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE, Schinke T, Mautner VF, Amling M (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21:119-127
39. Shapira S, Barkan B, Friedman E, Kloog Y, Stein R (2007) The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 14:895-906 (Pubitemid 46629829)
40. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D'Astous JL, Santora SD, Viskochil DH (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143-148 (Pubitemid 43927385)
41. Viskochil D (2002) Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 17:562-570 discussion 571-572, 646-651 (Pubitemid 35203615)
42. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17-25 (Pubitemid 43089652)
43. Weinstein RS, Harris RL (1990) Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis. Calcif Tissue Int 46:361-366 (Pubitemid 20176233)
44. Writing Group for the ISCD Position Development Conference (2004) Position statement : executive summary. J Clin Densitom 7:7-12
45. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW (2006) Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880-2891 (Pubitemid 44684473)
46. Young H, Hyman S, North K (2002) Neurofibromatosis 1. clinical review and exceptions to the rules. J Child Neurol 17:613-62.
47. Zhu Y, Parada LF (2001) Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 264:19-28 (Pubitemid 32989078)